Drug Landscape ›
2-MERCAPTOETHANESULFONIC ACID ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 11
Most-reported reactions
Urinary Tract Infection — 2 reports (18.18%) Back Pain — 1 report (9.09%) Disease Recurrence — 1 report (9.09%) Hepatotoxicity — 1 report (9.09%) Infection Reactivation — 1 report (9.09%) Neutropenia — 1 report (9.09%) Pneumocystis Jiroveci Pneumonia — 1 report (9.09%) Streptococcal Sepsis — 1 report (9.09%) Temporal Arteritis — 1 report (9.09%) Treatment Failure — 1 report (9.09%)
Source database →
2-MERCAPTOETHANESULFONIC ACID in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is 2-MERCAPTOETHANESULFONIC ACID approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for 2-MERCAPTOETHANESULFONIC ACID in United States?
Marketing authorisation holder not available in our data.